Clinical trial using carlumab monotherapy, a human IgG1k monoclonal antibody against CCL2, had little success in patients with advanced solid tumors and metastatic prostate cancer, however, results from CCL2 blockade with immune checkpoint blockade have yet to be reported (Pienta et al., 2013; Sandhu et al., 2013). This evidence concerns the gene CCL2 and metastatic prostate carcinoma.